We are pleased to highlight the contribution of Dr. Eva Blondeaux to the latest publication in the Journal of the National Cancer Institute (published February 5, 2025), titled:
“Prognostic implications of risk definitions from the monarchE and NATALEE trials.”
The study, co-authored by experts including Luca Arecco, Michelino De Laurentiis, Lucia Del Mastro, and Evandro de Azambuja, offers a crucial analysis of how differing trial definitions of “high risk” impact prognostic stratification in patients with HR+/HER2− early breast cancer.
By comparing monarchE and NATALEE eligibility criteria across nearly 4,800 patients, the team provided insights that could guide more precise selection of candidates for adjuvant therapy escalation.
Congratulations to Dr. Eva Blondeaux and the team on this impactful work in refining real-world risk assessment in early breast cancer.
Read the study here: https://lnkd.in/ddFWzNF6
